氯沙坦联合超声激励微泡空化治疗肝癌的疗效评估
该研究在HCC小鼠模型中评估氯沙坦与超声激励微泡空化（USMC）联合治疗的疗效，采用超声分辨显微术（URM）和超声黏弹性成像（UVI）无创监测血管与力学反应。联合治疗组血流速度增加、微血管密度和灌注指数降低、黏弹性参数显著下降，肿瘤体积在所有治疗组均显著缩小，CD34阳性微血管减少。结论认为低和高机械指数USMC增强血管通透性并诱导血管破坏，氯沙坦降低基质硬度，二者联合产生协同治疗效应。
要点
- URM可定量微血管密度、密度比、血流速度及灌注指数，用于评估USMC后血管反应。
- UVI可检测弹性、黏度及频散系数，反映氯沙坦降低基质硬度的效果。
- USMC联合氯沙坦组血流速度升高且黏弹性参数下降最显著，提示协同效应。
核心结论
- 低和高机械指数USMC增强血管通透性并诱导血管破坏，氯沙坦降低基质硬度，二者联合对HCC产生相加治疗效应。
- URM和UVI可无创、互补地评估机械治疗和空化治疗过程中的血管与力学反应。
研究设计与样本
- 研究类型为动物实验，使用C57BL/6小鼠诱导HCC模型（6周时肝内植入Hepa1-6细胞）。
- 小鼠分为五组：氯沙坦单药组、USMC单药组、联合组（氯沙坦+USMC）、未治疗HCC组和健康对照组。
- 氯沙坦隔日给药；USMC共 delivery 五次（三次低机械指数 session 后两次高机械指数 session）。
- 在首次USMC治疗前和末次治疗后行URM和UVI检查。
- 处死时分析肿瘤体积、肝/体重比及CD34染色。
关键影像表现/征象
- URM显示联合组平均血流速度从9.7 ± 2.00 mm/s增至13.1 ± 1.59 mm/s（p = 0.006）。
- USMC治疗组微血管密度、密度比和灌注指数降低。
- 三个治疗组治疗后黏弹性均下降，且低于未治疗HCC组但高于健康对照组；联合组下降显著（弹性p = 0.006；黏度p = 0.028；频散p < 0.001）。
- 所有治疗组肿瘤体积均显著缩小（p < 0.001）。
- CD34染色显示USMC组和联合组微血管阳性率降低。
临床应用与阅片要点
- URM可定量微血管密度、密度比、血流速度和灌注指数，用于监测USMC治疗后血管变化。
- UVI可评估弹性、黏度和频散系数，反映氯沙坦对基质硬度的降低作用。
- 联合治疗组血流速度增加而微血管密度和灌注指数降低，提示血管通透性增强和血管破坏并存。
- 黏弹性参数在治疗后下降但未恢复至健康水平，需结合未治疗HCC和健康对照进行判读。
局限性
- 研究为动物实验（小鼠HCC模型），结果外推至人类需进一步验证。
- 样本量小且未报告随机化、盲法及统计效能等细节。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
OBJECTIVES: To investigate the combined therapeutic effects of "mechanotherapeutic" agent losartan and ultrasound-stimulated microbubble cavitation (USMC) on hepatocellular carcinoma (HCC).
METHODS: C57BL/6 mice were assigned to five groups: losartan only, USMC only, combination (losartan+USMC), untreated HCC, and healthy controls. HCC was induced via intrahepatic implantation of Hepa1-6 cells at 6 weeks. Losartan was administered every other day. USMC was delivered five times (three sessions with low mechanical index (MI) followed by two sessions with high MI). Ultrasound resolution microscopy (URM) and ultrasound viscoelastic imaging (UVI) were performed before the first and after the last USMC treatment. URM quantified microvascular density, density ratio, blood-flow velocity, and perfusion index; UVI assessed elasticity, viscosity, and dispersion coefficients. Tumor volume, liver/body weight, and CD34 staining were analyzed at sacrifice.
RESULTS: After USMC treatment, mean blood-flow velocity increased in combination group (9.7 ± 2.00 to 13.1 ± 1.59 mm/s, p = 0.006) and microvascular density, density ratio, and perfusion index reduced in USMC-treated groups. Viscoelasticity in three treated groups decreased after treatment and remained lower than untreated HCC but higher than healthy controls, with significant decline in the combination group (elasticity p = 0.006; viscosity p = 0.028; dispersion p < 0.001). Tumor volume was significantly reduced in all treated groups (p < 0.001). CD34 staining showed lower microvascular positivity in the USMC and combination groups.
CONCLUSIONS: Low- and high-MI USMC enhanced vascular permeability and induced vascular disruption, while losartan reduced stromal stiffness. Their combination produced additive therapeutic effects on HCC. URM and UVI provide complementary, noninvasive assessment of vascular and mechanical responses during mechanotherapeutic and cavitation-based treatments.
引用
- Li X, Numata K, Zhang J, et al. Evaluation of the Efficacy of Combined Treatment of Liver Cancer With Losartan and Ultrasound‑Stimulated Microbubble Cavitation. Ultrasound Med Biol. 2026. PMID: 42203545. doi:10.1016/j.ultrasmedbio.2026.04.026
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。